Company Overview and News
Indian Hume Pipe Company has received Letter of Acceptance for ₹221.72 crore from Madhya Pradesh Jal Nigam Maryadit (A Government of Madhya Pradesh Undertaking) for EPC work of various components of Indwar-1 Multi Village Rural Water Supply Scheme at Umaria and Katni on turnkey basis, including trial run & maintenance of the entire scheme for 10 years.
Bearish momentum continued on D-Street for the second consecutive day on Tuesday as a sharp selloff in the last hour dragged the market. The Nifty breached 11,300-mark and ended below it, while the Sensex closed around 300 points lower.
YESBANK 539336 HINDUNILVR 532648 YYBKY 532401 VIJAYABANK GUJGAS 532121 INDIANHUME 500696 500570 504741 TATAMOTORS DENABANK SBAZ TTM
Indian Hume Pipe Company on Monday signed a Memorandum of Understanding with Kalpataru Gardens Pvt Ltd, the Developer, (a wholly-owned subsidiary of Kalpataru) for development of the company’s land at Vadgaon, Pune. The company has given the Power of Attorney to the Developer for obtaining approvals, sanctions, permissions and NOCs relating to the project. Shareholders will closely monitor the execution and further development of the project.
It’s not a result that the bulls would have anticipated, considering the pullback it had on September 7, 2018. A weak rupee, which fell to record lows of 72.67 per US dollar weighed heavily on indices. The Indian currency saw weak moves following macro concerns on the domestic front along with having spillover effects of a selloff in emerging market currencies too.
INDIANHUME 500570 504741 TATAMOTORS TTM
Mumbai: Mumbai-based real estate firm Kalpataru Ltd has entered into a joint development agreement with pipe manufacturer Indian Hume Pipe Co. Ltd, to develop a 15-acre land parcel for a residential project in suburban Pune.
GODREJPROP INDIANHUME 533150 504741
Indian Hume Pipe Company has received a work order of ₹256.19 crore from the Tamil Nadu Water Supply & Drainage Board, Coimbatore. The order is for providing combined water supply scheme to Alampalayam Town Panchayat, Padaveedu Town Panchayat including 669 rural habitations in Pallipalayam and Tiruchengode Unions in Namakkal District, and Sankari Town Panchayat in Salem District with river Cauvery as source.
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
JSGRY SOMANYCERA KAJARIACER HINDUNILVR 531548 CERA JSGCF RB 5938 532443 INDIANHUME 500233 500696 504741
The market fell sharply from its day's high to end below the flatline amid uncertainty over formation of the government in Karnataka after election results.
500325 BHUSANSTL RELIANCE KTKBANK 533278 535789 500470 532121 532461 RIGD 532480 HDFCBANK BJJQY 500570 TATAMOTORS CLNDY 500055 RLNIY 500034 KMBKY IBN IDKQY ALBK 532605 532843 JBMA IBULHSGFIN 532652 ICICIBANK BAJFINANCE TTST PNJZY INDIANHUME TATASTEEL FORTIS TATLY HDB 532174 500180 KOTAKBANK PNB 500247 504741 DENABANK COALINDIA TTM
Market Closing: Benchmark indices ended flat after the BJP is likely to fail to reach half-way mark in Karnataka, though it is likely to be emerging as the largest party with 104 seats.
BALAJITELE PWQFY 539150 500325 EMAMIINFRA 500800 BHUSANSTL TTAZF 532714 TTAEY 539437 TGBL 532121 532162 532480 500570 500055 RLNIY ALBK JETAIRWAYS JBMA ZANDUREALT TATASTEEL TATLY 504741 506720 PFS 539254 RELIANCE 532617 KTKBANK PNCINFRA 532810 500470 IDFCBANK 532461 RIGD 532382 KEC TATAMOTORS SNOWMAN ADANITRANS JKPAPER INDIGO TGBA IBN 532605 533344 538635 539448 PFC 532652 ICICIBANK 533218 TTST PNJZY INDIANHUME 532174 PNB TATAGLOBAL DENABANK TTM
Earnings: Pharma major Lupin has posted a loss of Rs 783.5 crore for the quarter ended March 2018, due to one-time loss of Rs 1,464.3 crore on Gavis Group acquisition.
PWQFY 539150 500325 EMAMIINFRA BHUSANSTL RELIANCE PNCINFRA 532810 539437 500470 IDFCBANK RIGD 500570 SNOWMAN TATAMOTORS 500055 RLNIY INDIGO IBN 532605 JBMA 538635 539448 PFC ICICIBANK 533218 ZANDUREALT TTST INDIANHUME TATASTEEL TATLY 532174 504741 506720 TTM
Shares of Indian Hume Pipe Company declined 4 percent intraday Tuesday as company received cancellation of letter of acceptance from Madhya Pradesh Jal Nigam Maryadit.
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...